SCHEDULE 13D/A: Suvretta Capital and Affiliates Increase Stake in Benitec Biopharma to 49.9% Through Direct Offering

Suvretta Capital Management and its affiliated funds, Averill Master Fund and Averill Madison Master Fund, have significantly increased their beneficial ownership in Benitec Biopharma Inc. to 49.9% following a registered direct offering.

Summary

• Suvretta Capital Management, LLC and its affiliated funds (Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.) have increased their beneficial ownership in Benitec Biopharma Inc.
• The increase stems from a registered direct offering completed on March 26, 2025, where the funds purchased a total of 900,000 shares of Common Stock at $13.00 per share.
• Averill Master Fund purchased 793,800 shares, and Averill Madison Master Fund purchased 106,200 shares, totaling $11.7 million in new investment from their working capital.
• Following this transaction, Suvretta Capital Management, LLC and its control person, Aaron Cowen, beneficially own 15,623,659 shares, representing 49.9% of the outstanding Common Stock.
• This 49.9% ownership includes previously held shares, shares from the direct offering, and shares issuable upon the exercise of warrants, subject to a 49.9% ownership limitation.
• The total outstanding shares of Common Stock used for calculation are 31,309,938, comprising 25,546,288 shares outstanding as of March 26, 2025, plus 5,763,650 shares issuable from warrants.
• A Registration Rights Agreement was also executed, obligating Benitec Biopharma to file a registration statement within 60 days to allow for the resale of the newly purchased shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant capital raise and increased institutional ownership indicate confidence and provide financial stability. However, the dilution for existing shareholders and the 49.9% ownership limitation on warrants temper the overall positivity.

Positives

• Significant capital infusion of $11.7 million into Benitec Biopharma Inc. from institutional investors.
• Increased commitment and confidence from a major institutional investor (Suvretta Capital Management and its affiliates) in Benitec Biopharma, as evidenced by their increased stake to 49.9%.
• The direct offering provides immediate funding to the Issuer.

Negatives

• The direct offering likely resulted in dilution for existing shareholders not participating in the offering, as new shares were issued.
• The 49.9% ownership limitation with respect to warrants suggests a cap on the investor's immediate voting power, potentially limiting their influence despite a large stake.

Risks

• Potential for future dilution if the warrants held by the reporting persons are fully exercised, although subject to a 49.9% ownership limitation.
• Regulatory risk associated with the Issuer's obligation to file a registration statement for resale of the shares within 60 days and keep it effective. Failure to do so could have consequences.

Future Outlook

The Issuer has committed to filing a registration statement within 60 days following the closing of the Direct Offering to register the shares purchased by the Funds for resale. The Issuer also agreed to use its best efforts to ensure the registration statement is declared effective promptly and remains effective until the shares can be sold without restrictions.

Industry Context

This filing indicates a significant capital infusion into a biopharma company from institutional investors, which is a common method for funding research and development or operational needs in the capital-intensive biotechnology sector. The substantial stake acquired by Suvretta Capital Management suggests a strong belief in Benitec Biopharma's future prospects, potentially signaling a positive outlook within the specialized biopharma investment landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders**: Existing shareholders not participating in the direct offering experienced dilution due to the issuance of new shares. However, the capital raise provides funding for the company's operations, which could benefit long-term shareholder value.
• **Investors (Suvretta Capital Management and affiliates)**: These investors significantly increased their stake, demonstrating strong conviction in the company's prospects and gaining substantial influence, albeit with a 49.9% ownership limitation on warrant exercise.
• **Company (Benitec Biopharma Inc.)**: The company received $11.7 million in capital, which can be used for operations, research, and development, strengthening its financial position.

Next Steps

• Benitec Biopharma Inc. is obligated to file a registration statement for the resale of the newly issued shares within 60 days following the closing of the Direct Offering (by approximately May 25, 2025).
• The Issuer must use best efforts to ensure the registration statement is declared effective promptly by the SEC and remains effective until the Registrable Securities can be sold without volume or manner-of-sale restrictions.

Key Dates

Recommendation

Keywords

Benitec Biopharma Inc., Suvretta Capital Management, Direct Offering, SEC Schedule 13D, Common Stock, Share Ownership, Institutional Investment, Capital Raise, Registration Rights Agreement, Biopharma